Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers

NCT06840119 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT06840119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06840119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers
Lead sponsor
Immunocore Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 10, 2024
Completion date
November 30, 2027
Enrollment
600 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, hla-a*02:01-positive